Cerivastatin and reports of fatal rhabdomyolysis.

By J. Staffa, Jennie T. Chang, L. Green. New England Journal of Medicine, 2002

655 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Surgery, Toxicology

View Paper: https://www.semanticscholar.org/paper/7b0db1edc27b1e4db62281f1ed96140b900b0828

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. Santiago Vilar
2. Carol Friedman
3. George Hripcsak
4. S. Grundy

In Surgery

1. Santiago Vilar
2. Carol Friedman
3. George Hripcsak
4. S. Grundy
5. J. Tobert

In Toxicology

1. Santiago Vilar
2. Carol Friedman
3. George Hripcsak

Citations in the corpus

• Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association (2019, positive): “Regulatory agencies determined that the risk of rhabdomyolysis associated with cerivastatin across the dosage range was much higher than for other statins, and it was withdrawn worldwide in August 2001.(23,50) It is still unclear why cerivastatin is so much more myotoxic than other statins.”
• The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease (2002, neutral): “Number of mice per group in each experiment: a (7), b (14), c (10), d (10), e (7) and f (7).”
• Organic Anion Transporting Polypeptide 1B1: a Genetically Polymorphic Transporter of Major Importance for Hepatic Drug Uptake (2011, background): “The clinical spectrum of statin-induced myopathy ranges from a mild and relatively common myalgia (5–10% of statin users/year) to a life-threatening and rare rhabdomyolysis (0.001–0.005% of statin users/year) (Staffa et al., 2002; Graham et al., 2004).”
• Bench-to-bedside review: Rhabdomyolysis – an overview for clinicians (2004, neutral): “15 deaths per one million prescriptions [64].”
• Drug interactions with lipid‐lowering drugs: Mechanisms and clinical relevance (2006, background): “Many of these cases occurred in patients using gemfibrozil and cerivastatin concomitantly”
• Detection of drug‐drug interactions through data mining studies using clinical sources, scientific literature and social media (2018, positive): “For instance, cerivastatin, a drug that lowers cholesterol levels by inhibiting the enzyme HMG-CoA reductase, was withdrawn from the pharmaceutical market worldwide in 2001 because of 52 cases of fatal rhabdomyolysis [11, 12].”
• Mild to Moderate Muscular Symptoms with High-Dosage Statin Therapy in Hyperlipidemic Patients —The PRIMO Study (2005, background): “Moreover, fluvastatin treatment has also been associated with the lowest number of published cases of rhabdomyolysis [30], and the lowest published incidence of fatal rhabdomyolysis [12], among statins in clinical practice.”
• ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. (2002, background): “The FDA report comparing the rate of fatal rhabdomyolsis among different statins is of considerable importance (10).”